Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Acetylcholine (ACh) release at the presynaptic terminal is a fundamental process in cholinergic neurotransmission, occurring at both central and peripheral synapses. In this process, ACh is stored in vesicles within the presynaptic neuron. Upon stimulation—typically an action potential—these vesicles fuse with the presynaptic membrane and release ACh into the synaptic cleft, where it can bind to postsynaptic receptors. The process is tightly regulated by voltage-gated calcium channels, SNARE proteins, and presynaptic autoreceptors (muscarinic and nicotinic) that modulate the amount and timing of ACh release. Disruptions in this process are implicated in various neurological disorders.
Modulation of acetylcholine release via various mechanisms, including vesicle fusion inhibition (Botulinum toxin) or massive release stimulation (Black widow spider venom). Acetylcholinesterase inhibitors increase acetylcholine availability.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Acetylcholine Release (Presynaptic).